Acadia Pharmaceuticals | ACAD - Trade Creditors


Acadia Pharmaceuticals reported $16.33M in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
ALKERMES USD 107.69M 35.17M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Cara Therapeutics USD 4.62M 1.4M Mar/2026
Corcept Therapeutics USD 21.92M 7.01M Sep/2026
Cytokinetics USD 25.96M 5.45M Sep/2026
Eisai JPY 87.53B 11.64B Jun/2026
Eli Lilly USD 5.79B 319M Sep/2026
Incyte USD 235.37M 1.16B Sep/2026
J&J USD 9.32B 94M Sep/2026
Moderna USD 259M 92M Sep/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
Prothena USD 1.69M 249K Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026